EGFR and glioblastoma: The interplay of these effects transforms a “cold” TME into a “hot” TME with increased immune cells, providing a rationale to combine OV, or specifically OV-IL-15C, with EGFR-CAR-NK cells, for targeting heterogeneous glioblastoma.